

Sumatriptan non-responders: evaluation of a possible biomarker.

No registrations found.

Ethical review	Positive opinion
Status	Recruiting
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON27172

Source

NTR

Brief title

SNEB

Health condition

Migraine

Sponsors and support

Primary sponsor: Erasmus MC

Source(s) of monetary or material Support: Hersenstichting Nederland

Intervention

Outcome measures

Primary outcome

Percentage of change in dermal blood flow response to capsaicin application and saline iontophoresis after sumatriptan or placebo administration.

Secondary outcome

- Heat sensation after capsaicin application
- Blood pressure changes after sumatriptan use

Study description

Background summary

N/A

Study objective

Sumatriptan can block the increase in dermal blood flow (DBF) caused by application of capsaicin or electrical stimulation.

Study design

Start recruitment: 10-09-2013

Intervention

S.C. injection of sumatriptan

Contacts

Public

Erasmus MC
A.H. Meiracker, van den
's Gravendijkwal 230
Rotterdam 3015 CE
The Netherlands
+31-10-4639222

Scientific

Erasmus MC
A.H. Meiracker, van den
's Gravendijkwal 230
Rotterdam 3015 CE
The Netherlands
+31-10-4639222

Eligibility criteria

Inclusion criteria

- Age between 18 and 50 years
- Male or female
- Females should use an oral contraceptive pill
- Non-smoking for > 6 months
- Body mass index between 18 and 30 kg/m²
- Capable and willing to give informed consent
- General good health, based on medical history and physical examination

Exclusion criteria

- History of cardiovascular disease
- Perimenopausal status of females
- Any serious illness that can compromise study participation
- Use of any medication (e.g., NSAIDs, other analgesics) < 48 hrs before the study
- Dermal diseases at the upper frontal side of the face
- Pregnancy or breastfeeding
- History of sensitivity to the fruits of capsicum plants (e.g. chilli peppers)
- Alcohol or drug abuse

Study design

Design

Study type:	Interventional
Intervention model:	Crossover
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	10-09-2013
Enrollment:	21
Type:	Anticipated

Ethics review

Positive opinion	
Date:	10-09-2013
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL3999

Register

NTR-old

Other

ISRCTN

ID

NTR4171

: Erasmus MC MEC-2012-326

ISRCTN wordt niet meer aangevraagd.

Study results

Summary results

N/A